Lilly’s Orna acquisition will see the company throw its hat into the in vivo cell therapy ring, which is garnering significant attention from investors and companies alike. Image credit: ChrisStock82 via ShutterStock.com.
Eli Lilly is acquiring
in vivo
cell therapy-focused biotech, Orna Therapeutics, in an immunology deal worth up to $2.4bn.
Through the agreement, Lilly will gain access to Orna’s new class of circular RNA (circRNA) and lipid nanoparticle-based therapies, which are designed to trigger the creation of therapeutic proteins by a recipient’s immune system to treat autoimmune diseases
in vivo
.
ORN-252 lies at the heart of this deal, which Orna is developing to treat B-cell-driven autoimmune diseases. The
in vivo
CAR-T therapy targets the CD19 lymphocyte surface antigen and is set to enter clinical trials.
According to Orna, preclinical trials on its circRNA platform have demonstrated promising efficacy signals – triggering more durable expression of therapeutic proteins than other RNA or cell therapy platforms. In the company’s eyes, this means that its platform could “unlock treatments that are not feasible with current RNA or cell therapy platforms”.
Eli Lilly’s Orna acquisition closely follows a flurry of high-value deals the company has made in early 2026 – including a
$1.12bn development and licensing agreement
with hearing loss gene therapy biotech, Seamless Therapeutics, as well as its
$1.2bn acquisition
of inflammatory specialist, Ventyx.
It also marks another addition to Lilly’s growing
cell and gene therapy (CGT)
pipeline, which has seen a number of inclusions between 2020 and 2025. According to GlobalData, parent company of
Pharmaceutical Technology
, the big pharma company signed 27 CGT deals during this period.
GlobalData Strategic Intelligence
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
Learn more about Strategic Intelligence
Across the business, Eli Lilly is looking to continue its successful sales streak after a positive FY2025, which saw the company
achieve 45% sales growth
through the strong performance of its obesity portfolio. The ballooning profits brought in by its cardiometabolic franchise also led Lilly to make history by becoming the first healthcare company to join the
$1tn market cap club
, a status currently occupied primarily by tech giants like NVIDIA and Apple.
In vivo
cell therapies catch industry attention
CGTs have long been a talking point across the pharmaceutical industry, as companies within the space look to mitigate their associated
commercialisation
and
chemistry, manufacturing & controls (CMC)
challenges.
While investors and pharma companies alike
back away from the traditional autologous therapy models
, many are now betting on
in vivo
CAR-T alternatives, which are less complex and expensive to manufacture. They also
sidestep the patient-related challenges
associated with
ex vivo
models, as recipients do not have to undergo lymphodepletion or treatment with bridging therapies prior to dosing.
As the buzz around this new cell therapy form grows, several big pharma players have invested in the technology – including Illinois-based pharma AbbVie, which
bought out
in vivo
CAR-T specialist, Capstan Therapeutics
for up to $2.1bn in July 2025.
Gilead Sciences-owned Kite Therapeutics later made a similar bet on Interius BioTherapeutics,
handing over $350m to acquire the company
and its
in vivo
CAR-T pipeline in August 2025.
BMS also followed suit by merging with Orbital Therapeutics
in a $1.5bn deal – further expanding the company’s CAR-T portfolio.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva
.
Editorial content is independently produced and follows the
highest standards
of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free eBook
Navigating cell therapy process development
The cell therapy manufacturing sector is rapidly evolving, driven by the need to balance innovative process development with rigorous GMP standards. This eBook, brought to you by industry leaders Cytiva, explores how biotech firms can address common challenges — including minimizing contamination risks from manual processes, overcoming resource limitations, and creating scalable, robust designs. Industry experts discuss strategies including automation, strategic outsourcing, and flexible equipment selection to streamline processes and reduce regulatory risks. To unlock expert insights on optimizing your cell therapy pathway from clinical development to commercialization, fill in your details now.
Thank you.
You will receive an email shortly. Please check your inbox to download the eBook.
By Cytiva Thematic
You have a right to withdraw your consent at any time, by
clicking here
. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our
privacy policy
.
